Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study
Key result
Higher baseline adiponectin concentrations were associated with an increased risk of cardiovascular events in patients with manifest coronary artery disease (HR 1.02; 95% CI 1.0-1.04; P=0.012).
Why the study?
Is baseline adiponectin concentration associated with adverse cardiovascular outcomes in patients with manifest coronary artery disease?
Population
1,890 consecutive patients with documented coronary artery disease, including 1,130 with stable angina and…
Comparison
Baseline adiponectin concentrations vs Lower vs higher quartiles/levels of baseline…
Design
Cohort
Follow-up
median 2.5 years
Authors
Discussion
Loading...
Member takes
Implication
Adiponectin should not guide risk assessment in manifest CAD; leaves open its incremental value beyond BNP.
Study Design
Type
Cohort (n=1,890)
Structured PICO
Is baseline adiponectin concentration associated with adverse cardiovascular outcomes in patients with manifest coronary artery disease?
P
Population
1,890 consecutive patients with documented coronary artery disease (CAD), including 1,130 with stable angina (SAP) and 760 with acute coronary syndrome (ACS).
I
Intervention
Baseline adiponectin concentrations
C
Comparator
Lower vs higher quartiles/levels of baseline adiponectin
O
Outcome
Cardiovascular events (cardiovascular deaths and non-fatal myocardial infarction) over a median follow-up of 2.5 yearshard clinical
Main Result
Effect estimate: HR 1.02 (95% CI 1.0-1.04)
p-value: p=0.012
In patients with manifest CAD, higher baseline adiponectin levels are associated with an increased risk of adverse cardiovascular events, though this predictive value is not independent of BNP.
Cite This Study
Schnabel et al. (2008) conducted a cohort in Coronary artery disease (n=1,890). Adiponectin concentration was evaluated on Cardiovascular events (cardiovascular deaths and non-fatal myocardial infarction) (HR 1.02, 95% CI 1.0-1.04, p=0.012). Higher baseline adiponectin concentrations were associated with an increased risk of cardiovascular events in patients with manifest coronary artery disease (HR 1.02; 95% CI 1.0-1.04; P=0.012).